ReviewNature reviews. Clinical oncology2014
Bilateral breast cancers.
Review in Nature reviews. Clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta-analysis of studies from recent decade (2008-2018).Cancer medicine · 2019Pooled it
- Risk-reducing mastectomy for the prevention of primary breast cancer.The Cochrane database of systematic reviews · 2018Pooled it
- The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study.Breast cancer research : BCR · 2018Trial
- Dosimetric comparison of three different radiotherapy regimens for bilateral breast cancer.Biomedical engineering online · 2026Article
- Right breast invasive carcinoma and contralateral left axillary abscess representing a rare dual pathology.Discover oncology · 2026Article
- Illuminating Bilateral Breast Cancer: A Multicenter Experience and Clinical Observations.Medicina (Kaunas, Lithuania) · 2025Article
- Patient-Derived Organoids for Guiding Neoadjuvant Chemotherapy in Bilateral Primary Breast Cancer: A Case Report.OncoTargets and therapy · 2025Article
- Patient-derived organoid elucidates the identical clonal origin of bilateral breast cancer with diverse molecular subtypes.Frontiers in oncology · 2024Article
- Article
- Satisfaction and Well-Being After Contralateral Prophylactic Mastectomy Among BRCA Mutation Carriers and Noncarriers: A Longitudinal Analysis of BREAST-Q Domains.Annals of surgical oncology · 2023Article
- A study of clinical and molecular characteristics in bilateral primary breast cancer.Cancer medicine · 2023Article
- The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk inCancers · 2023Article
- Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003-2017).Breast cancer research and treatment · 2022Article
- Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer.Frontiers in oncology · 2022Article
- Effect of breast-conserving surgery plus radiotherapy versus mastectomy on breast cancer-specific survival for early-stage contralateral breast cancer.Gland surgery · 2021Article
- Choosing Mastectomy vs. Lumpectomy-With-Radiation: Experiences of Breast Cancer Survivors.Cureus · 2021Article
- Retrospective Analysis of Clinicopathological Features and Familial Cancer History of Synchronous Bilateral Breast Cancer.Healthcare (Basel, Switzerland) · 2021Article
- Objective photographic assessments and comparisons of immediate bilateral breast reconstruction using deep inferior epigastric perforator flaps and implants.Archives of plastic surgery · 2021Article
- Bilateral breast cancer in China: A 10-year single-center retrospective study (2006-2016).Cancer medicine · 2021Article
- The risk of contralateral breast cancer: a SEER-based analysis.British journal of cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasingly large proportion of women with unilateral breast cancer are treated with bilateral mastectomy. The rationale behind bilateral surgery is to prevent a second primary breast cancer and thereby to avoid the resultant therapy and eliminate the risk of death from contralateral breast cancer. Bilateral mastectomy has been proposed to benefit women at high risk of contralateral cancer, such as carriers of BRCA1 and BRCA2 mutations, but for women without such mutations, the decision to remove the contralateral breast is controversial. It is important to evaluate the risk of contralateral breast cancer on an individual basis, and to tailor surgical treatment accordingly. On average, the annual risk of contralateral breast cancer is approximately 0.5%, but increases to 3% in carriers of a BRCA1 or BRCA2 mutation. Risk factors for contralateral breast cancer include a young age at first diagnosis of breast cancer and a family history of breast cancer. Contralateral mastectomy has not been proven to reduce mortality from breast cancer, but the benefit of such surgery is not expected to become apparent until the second decade after treatment. An alternative to contralateral mastectomy is adjuvant hormonal therapy (such as tamoxifen), but the extent of risk reduction is smaller (approximately 50%) compared to 95% or more for contralateral mastectomy. This Review focuses on the risk factors for contralateral breast cancer, and discusses the evidence that bilateral mastectomy might reduce mortality in patients with unilateral breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.